SUBSCRIBE TO OUR FREE NEWSLETTER
Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.
5
#000000
#FFFFFF
5
#000000
#FFFFFF
us food and drug administration
'Is the President Telling the Truth?' Sanders Corners Trump FDA Nominee on His Bogus Drug Price Claims
"Wow! The American people are so excited to know now that!" US Sen. Bernie Sanders sarcastically said of Trump's false prescription drugs claim.
Sep 24, 2026
Sen. Bernie Sanders on Thursday grilled President Donald Trump's nominee to lead the US Food and Drug Administration about the president's false claims about the price of prescription drugs in the US.
During a Senate confirmation hearing, Sanders (I-Vt.) asked Dr. Heidi Overton about Trump's boast at this year's State of the Union address about giving Americans the cheapest medications of any country in the world.
“President Trump has claimed... that he took prescription drugs from the highest price in the entire world to the lowest,” Sanders said in an incredulous tone.
“Wow!" he continued sarcastically. "The American people are so excited to know now that we pay the lowest prices in the world for prescription drugs.”
BERNIE SANDERS: Trump claims we pay the lowest prices in the world for prescription drugs. Wow! Is the president telling the truth?
FDA NOMINEE HEIDI OVERTON: There has been immense progress--
SANDERS: Do we pay the lowest prices like the president said? You just told us you… pic.twitter.com/X7gWNbSmik
— Aaron Rupar (@atrupar) September 24, 2026
"What do you think?" Sanders asked Overton. "Are we paying the lowest prices in the world for prescription drugs?"
"Senator... there has been immense progress, especially on individual products," Overton replied. "Right now, 89% of branded drugs have signed agreements to lower their prices and make that available..."
Sanders at this point interjected.
"Do we pay the lowest prices?" he asked. "The president said it. He's your boss... He just said we pay the lowest prices in the world for prescription drugs. It's true or it's not true. Is it true?"
"Senator, we have seen..." Overton began.
"Is it true that we pay the lowest prices in the world for prescription drugs, as President Trump has said?" Sanders persisted.
"So, senator, the results that we have seen for the American people... have dropped prices," she replied. "And right now [the Consumer Price Index] says that, for the first time in 60 years, prescription drug prices have gone down by 3%."
"Which may have something to do with the legislation that we passed several years ago," said Sanders, in reference to provisions in the 2022 Inflation Reduction Act that granted Medicare the power to negotiate lower prices for certain prescription drugs.
Even if Trump's policies were solely responsible for a 3% drop in drug prices, that would not make them the lowest in the world by any stretch of the imagination.
A 2024 study from the RAND Corporation found that Americans pay nearly three times as much for prescription drugs compared to the rest of the world.
Sanders' office last year released a report showing that, during the first year of Trump's second term, drug companies raised prices on 688 medications, with a median increase of 5.5%.
Trump has a long history of making false claims about reducing prescription drug costs, and has even said that he has slashed them by as much as 600%, which would mean that pharmaceutical companies are paying consumers to take their medications.
Keep ReadingShow Less
Court Lets US Abortion Pill Access Continue—Until Trump FDA Finishes Review Condemned as 'Sham'
A federal judge opted not to rule on a lawsuit seeking to overturn FDA approval of mifepristone until the FDA completes a review that has been described as a political pretext to restrict abortion.
Aug 31, 2026
Access to the abortion drug mifepristone will remain unchanged in the US for now after a federal district judge on Sunday paused a lawsuit aimed at overturning the Food and Drug Administration's approval of the medication. But he left the door open for the Trump administration to restrict access to the drug.
US District Judge Reed O'Connor of the Northern District of Texas refused the manufacturer's motion to dismiss a lawsuit brought by Texas and Florida seeking to overturn FDA approval of mifepristone altogether. But the judge accepted the US Department of Justice's (DOJ) motion to stay the case until December 1, or until the FDA completes a "review" of the drug that it will use to determine whether access to it should be tightened.
That FDA review, spearheaded by Health and Human Services Secretary Robert F. Kennedy Jr., has been criticized as a politicized effort to create a pretext for the anti-abortion Trump administration to restrict abortion pill access, including in states where the procedure is legal.
Nearly 700,000 people use mifepristone per year, according to the Guttmacher Institute, which has found it to be the method for the majority of US abortions in recent years.
Receiving it through the mail via out-of-state telehealth providers has become a go-to method for those in states with bans on terminating a pregnancy. The drug has been used by around 7.5 million people since it was first approved in 2000.
The FDA's own current webpage states that its periodic reviews of mifepristone have “not identified any new safety concerns” and that the drug is safe when used as directed. Prior FDA reviews have found that hospitalization occurs in only 0.04-0.6% of all medication abortions.
Despite the lack of any clearly identified risk, the Trump FDA has said that the ongoing review could lead to “substantive changes" to the Risk Evaluation and Mitigation Strategy for the drug, leading some to argue that it is a "sham" meant to create a scientific justification for the administration's goal of restricting abortion.
"Ensuring legal access to mifepristone in the long term is vital to women’s healthcare and reproductive freedom," said Evan Masingill, the CEO of GenBioPro, which manufactures generic mifepristone and sued to defend the FDA's approval of its product.
"We expect the FDA’s review of mifepristone to not contradict the decision they made in 2023 that reaffirmed our product is safe and effective," Masingill said.
The US Supreme Court ruled earlier this year that lower courts could not block the FDA's 2023 decision, under the Biden administration, to lift in-person dispensing requirements for mifepristone following the overturning of Roe v. Wade the previous year. The in-person requirement was lifted following a 2021 FDA review that deemed the rules unnecessary.
The Supreme Court has previously blocked individual anti-abortion doctors from bringing lawsuits against the FDA, ruling that they did not have standing to claim personal injury.
But Texas and Florida have sought to get around this by suing as states, and so far, courts have allowed them to do so. The conservative 5th Circuit accepted a similar argument from Louisiana earlier this year.
However, O'Connor—an appointee of former President George W. Bush—did not rule on the merits of whether the states' claims against the FDA were correct.
But even if that lawsuit fails, the Trump administration could dramatically curtail access to mifepristone by reinstating in-person dispensing requirements, placing new limits on which pharmacies can dispense the drug, and adding new requirements for prescribers and patients.
“The FDA has affirmed time and again that mifepristone is safe and effective,” said Skye Perryman, President and CEO of Democracy Forward, which is representing the drugmaker. “Far-right, anti-science extremists may be pressuring the Trump-Vance administration to reach a different, ideologically-driven outcome, but we will continue to represent our clients to hold the FDA to the same science-based standards it has long applied to protect people’s ability to access effective, evidence-based healthcare, including protecting access to medication abortion.”
Keep ReadingShow Less
Critics Slam Trump FDA Pick Heidi Overton as 'Anti-Reproductive Rights, Anti-Vax, Anti-Science'
"The American people deserve someone who will put science and facts FIRST, not another Trump sycophant who will make it their mission to attack medication abortion," said one Democratic senator.
Aug 19, 2026
President Donald Trump on Wednesday tapped White House health policy adviser Dr. Heidi Overton to lead the Food and Drug Administration, a move that drew fierce opposition from Democratic lawmakers, reproductive rights advocates, and public health experts, who pointed to her opposition to abortion rights and support for controversial changes to federal vaccine policy as cause for alarm.
Trump took to his Truth Social network to announce his pick of Overton, a physician and deputy director of the White House Domestic Policy Council, to replace former FDA Commissioner Marty Makary, who resigned in May following months of turmoil at the agency. The president described Overton as a "ROCKSTAR" in his administration who will "deliver on the MOST TRANSFORMATIVE Health Agenda in History."
"Heidi is 'ALWAYS RIGHT,' Secretary Kennedy recently said in the Oval Office!" Trump continued, referring to Health and Human Services chief Robert F. Kennedy Jr. "We need her leadership at the FDA now to ensure that the US remains the WORLD LEADER for Scientific Discovery and CURES."
The president also said Overton would work with Centers for Medicare & Medicaid Services Administrator Mehmet Oz to advance his agenda of faster drug approvals, increased innovation, clinical trial reforms, and lower prescription drug prices.
However, skeptics argue that Overton’s policy record raises serious questions about whether she would maintain the FDA’s scientific and regulatory independence in an administration in which critics say loyalty to Trump is of paramount importance.
Reproductive Freedom for All—formerly the National Association for the Repeal of Abortion Laws and NARAL Pro-Choice America—noted that "Overton has an extensive anti-abortion record."
The group continued:
She celebrated the overturning of Roe v. Wade as a “huge victory,” and has advocated for the politicization of government agencies to help advance a nationwide anti-abortion agenda. She previously worked at America First Policy Institute, an extreme conservative think tank made up of former Trump administration officials, where she authored a brief pushing disinformation about the safety of medication abortion and calling for additional, medically unnecessary restrictions on access to mifepristone.
“Donald Trump is trying to put an anti-abortion extremist in charge of any agency that could seriously undermine reproductive healthcare—including the agency that could roll back access to mifepristone nationwide," Reproductive Freedom for All president and CEO Mini Timmaraju said. "Her nomination is another alarming step in Trump’s plan to weaponize every part of the federal government to restrict abortion nationwide.”
Overton's shifting stance on vaccines also raised eyebrows.
Endpoints News senior senior reporter Max Bayer highlighted how, while working at AFPI, Overton "and others praised Operation Warp Speed, the massive government initiative to expedite development and manufacturing of the Covid-19 vaccines" during Trump's first administration.
But less than a year later, Bayer said, Overton "advocated against Covid-19 school vaccine mandates, writing in an editorial the data supported more parental choice in the decision."
"Overton stood by Trump earlier in August as he announced a sweeping and contentious new executive order amending the childhood vaccine schedule and advising that the [measles, mumps, and rubella] vaccine be broken up into individual components," he added. "Makers of the vaccine pushed back on the directive, but now with Overton in line to lead the FDA, there could be enhanced pressure for drugmakers to follow through on the request."
Democratic US lawmakers also voiced opposition to Overton's nomination.
"Heidi Overton is a far-right, anti-abortion extremist who has no business leading the FDA," Sen. Patty Murray (D-Wash.) said on social media. "The American people deserve someone who will put science and facts FIRST, not another Trump sycophant who will make it their mission to attack medication abortion. I will vote NO."
At least one Republican lawmaker—who chairs the Senate Health, Education, Labor, and Pensions Committee—also questioned Trump's pick.
"While I respect Dr. Overton’s experience as a physician, I have strong concerns about her nomination to be FDA commissioner," Sen. Bill Cassidy (R-La.), a gastroenterologist, said on X. "Her lack of managerial experience does not prepare her well for leading a large organization that is already dealing with staffing and morale issues."
"Additionally, Dr. Overton’s active role in last week’s nonsensical vaccine executive order calls into question her commitment to standing up for sound science and protecting children’s health. That alone is almost disqualifying," added Casisdy, who earlier this year lost a primary race to a Trump-backed challenger.
Overton's nomination comes amid turmoil at an agency that has seen thousands of employees fired by Kennedy since last year amid Trump administration efforts to shrink the government in line with Project 2025, the Heritage Foundation-led framework for a far-right federal overhaul.
Chris Meekins, a former Trump health official who is now an analyst at the investment bank Raymond James, told clients that Overton would be "like Makary, but probably worse."
“Being seemingly inexperienced and unqualified is fine if you have self-awareness and humility and a strong team around you,” Meekins wrote. “Based off of our DC channel checks, she does not seem to have either."
Keep ReadingShow Less
See More
Most Popular
To inform. To inspire. To ignite change for the common good.
News & Opinion
Trending
Common Dreams, Inc. Founded 1997. Registered 501(c3) Non-Profit
Privacy Policy